NKTR - Nektar Therapeutics

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
52.85
-3.01 (-5.39%)
At close: 4:00PM EDT

52.15 -0.70 (-1.32%)
Pre-Market: 8:08AM EDT

Stock chart is not supported by your current browser
Previous Close55.86
Open56.10
Bid52.15 x 1100
Ask53.00 x 900
Day's Range52.84 - 56.19
52 Week Range17.51 - 111.36
Volume5,592,582
Avg. Volume4,142,982
Market Cap9.059B
Beta2.72
PE Ratio (TTM)N/A
EPS (TTM)-0.81
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est96.78
Trade prices are not sourced from all markets
  • PR Newswire45 minutes ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Nektar Therapeutics for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , June 25, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • See what the IHS Markit Score report has to say about Nektar Therapeutics.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Nektar Therapeutics.

    Nektar Therapeutics NASDAQ/NGS:NKTR

  • Investopedia4 days ago

    Is Nektar Therapeutics Still a Good Bet Despite the Correction?

    Nektar Therapeutics (NASDAQ: NKTR) is a clinical-stage biotech research company that develops drugs for cancer, auto-immune diseases, and chronic pain using its PEGylation and polymer conjugate technology platforms. Earlier in Feb 2018, Nektar secured a deal with Bristol-Myers Squibb (NASDAQ: BMY) to co-develop NKTR-214, where BMY has agreed to pay $1.85 billion in a cash plus stock deal as payment to Nektar, as a result of which Nektar has not failed to leave investors’ radar. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this volatile stock.

  • TheStreet.com6 days ago

    Nektar Is the One S&P 500 Company Without a Woman Director

    is the only S&P 500 company without a woman on its board, representing a small improvement in gender diversity from last year. According to a May 31 dataset compiled by BoardEx, a relationship mapping service of TheStreet Inc., San Francisco-based Nektar has no female directors on its board. Meanwhile, eight S&P 500 companies have reached gender parity or greater in the boardroom, including Alliant Energy Corp.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Verastem and Nektar Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 18, 2018 / U.S. market plunged on Friday, but well-off session lows as investors appeared to look at previous signs of escalating trade tension between Washington and Beijing. ...

  • Nektar Therapeutics Closed Higher on June 14
    Market Realist10 days ago

    Nektar Therapeutics Closed Higher on June 14

    The S&P 500’s top gainers on June 14 were: Nektar Therapeutics (NKTR) gained 5.5%. Royal Caribbean Cruises (RCL) gained 5.1%. Comcast Corp A (CMCSA) gained 4.6%. Discovery Comm A (DISCA) gained 4.5%. Incyte (INCY) gained 4.4%. Nektar Therapeutics 

  • PR Newswire11 days ago

    New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting

    SAN FRANCISCO, June 14, 2018 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) in San Diego, California. "We are privileged that these meaningful new data from our clinical trials, as well as our translational research, were recognized for oral presentation at the prestigious CPDD meeting," said Steve Doberstein, Ph.D., Senior Vice President and Chief Research and Development Officer of Nektar Therapeutics.

  • Barrons.com14 days ago

    Former Incyte CEO Buys Slumping Nektar Shares

    Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...

  • Barrons.com14 days ago

    Biotech, Nektar Therapeutics Can't Handle Mondays

    Nektar Therapeutics (NKTR) went on a rollercoaster ride last week, and is down again today, following a downgrade, along with much of the rest of biotech. First, it notched a painful 40% plunge last Monday, in reaction to a presentation detailing its experimental drug NKTR-214 at a meeting at the American Society of Clinical Oncology, which didn't live up to high expectations.  Then, it bounced back for two days of gains of 6.5% and 7.2% on Tuesday and Wednesday, respectively, before the optimism ran out and it fell more than 11% on Thursday.  All of that movement means that while the intensely volatile shares are up 185% in the past 12 months, they've fallen more than 12% year to date. Today, the shares are down again, after H.C. Wainwright threw in the towel and downgraded Nektar to Neutral with a $54 price target.

  • Benzinga15 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

    The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves . Nektar Therapeutics (NASDAQ: NKTR ) slumped about 42 percent, while Deciphera Pharmaceuticals ...

  • See what the IHS Markit Score report has to say about Nektar Therapeutics.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Nektar Therapeutics.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • S&P 500’s Top Losses: Nektar Therapeutics and Lam Research
    Market Realist17 days ago

    S&P 500’s Top Losses: Nektar Therapeutics and Lam Research

    The S&P 500’s top losses on June 7 were: Nektar Therapeutics (NKTR) declined 11.7%. Seagate Technology (STX) declined 5.9%. Lam Research (LRCX) declined 5.4%. J.M. Smucker (SJM) declined 5.4%. Advanced Micro Devices (AMD) declined 5%. Nektar Therapeutics 

  • Why Nektar Therapeutics Stock Stumbled 11.8% Today
    Motley Fool17 days ago

    Why Nektar Therapeutics Stock Stumbled 11.8% Today

    Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.

  • Barrons.com18 days ago

    After the Bell: 21 Out of 30 Dow Stocks Can't Be Wrong, Can They?

    The Dow Jones industrial Average gained nearly 100 points even as everything else fell apart. The Nasdaq Composite, which had been rallied for four days, sank 0.7% to 7635.07, while the S&P 500 dipped 0.1% to 2770.37. "The Dow continued higher, but the NASDAQ Composite took a hit," writes Todd Market Forecast's Stephen Todd.

  • Nektar Therapeutics: S&P 500’s Top Gainer
    Market Realist18 days ago

    Nektar Therapeutics: S&P 500’s Top Gainer

    The S&P 500’s top gainers on June 6 were: Nektar Therapeutics (NKTR) gained 7.2%. Equifax (EFX) gained 6.1%. Dish Network (DISH) gained 5.8%. Devon Energy (DVN) gained 5.6%. Adv Micro Devices (AMD) gained 5.5%. Nektar Therapeutics 

  • What You Should Know about Nektar’s Cash Flows and Valuations
    Market Realist18 days ago

    What You Should Know about Nektar’s Cash Flows and Valuations

    Nektar Therapeutics (NKTR) used up $52.5 million on operating activities in Q1 2018 compared with $34.6 million in Q1 2017. Operating cash flow in Q1 2018 included $57.5 million of net operating cash use along with $5 million for interest payments on Nektar’s senior secured notes partially offset by the receipt of a milestone payment of $10 million from Baxalta. Nektar expects cash used in operating activities in fiscal 2018 to increase as compared with fiscal 2017 mainly as a result of higher research and development expenses.

  • Analyzing Nektar Therapeutics’ Operational Performance
    Market Realist18 days ago

    Analyzing Nektar Therapeutics’ Operational Performance

    Nektar Therapeutics’ (NKTR) cost of goods sold increased from $6.1 million in Q1 2017 to $6.6 million in Q1 2018. This increase was due to Nektar’s clinical development of NKTR-214, NKTR-181, and NKTR-262 and preclinical activities for NKTR-255. Nektar Therapeutics expects research and development expenses to increase significantly in fiscal 2018 as compared to fiscal 2017 mainly on account of the development of NKTR-214 under its collaboration agreement with Bristol-Myers Squibb.

  • Barrons.com19 days ago

    After the Bell: Dow Gains 346 Points and Didn't Need Tech to Do It

    The Dow Jones Industrial Average gained more than 300 points today. Today, it was the Dow's turn. The Dow got a huge lift from Boeing (BA), which rose 3.2% to $371.56, and added 78.91 points to the price-weighted benchmark.

  • Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today
    Motley Fool19 days ago

    Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today

    Find out which of these stocks picked up the most ground.

  • Here's Why Nektar Therapeutics Jumped as Much as 17% Today
    Motley Fool19 days ago

    Here's Why Nektar Therapeutics Jumped as Much as 17% Today

    The biopharma stock is bouncing after a wild week.

  • Nektar Attempts Recovery After Knocking $6 Billion Off Its Market Cap
    Investor's Business Daily19 days ago

    Nektar Attempts Recovery After Knocking $6 Billion Off Its Market Cap

    Nektar Therapeutics popped for the second day running Wednesday as it tried to recover from a melanoma presentation with Bristol-Myers Squibb.

  • How Was Nektar Therapeutics’ Top-Line Performance?
    Market Realist19 days ago

    How Was Nektar Therapeutics’ Top-Line Performance?

    In the first quarter of 2018, Nektar Therapeutics (NKTR) generated total revenues of $38 million compared with $24.7 million in the first quarter 2017. Nektar’s licensing and collaboration revenues rose more than 100% from $6 million in Q1 2017 to $13.7 million in Q1 2018. This increase was primarily due to the recognition of a milestone payment of $10 million received by Nektar in March 2018 resulting from the marketing authorization of Adynovi in the European Union in January 2018.

  • What’s the Upside Potential of Nektar Therapeutics?
    Market Realist19 days ago

    What’s the Upside Potential of Nektar Therapeutics?

    Nektar Therapeutics (NKTR) is a San-Francisco-headquartered biopharmaceutical company with a focus on research. It is developing drug candidates that make use of Nektar’s advanced polymer conjugate technology platforms. Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating, while one analyst has given it a “hold” rating.

  • What’s behind Nektar Therapeutics Stock’s Recent Price Tumble?
    Market Realist19 days ago

    What’s behind Nektar Therapeutics Stock’s Recent Price Tumble?

    After a stellar rise in the past 12 months, Nektar Therapeutics (NKTR) stock fell more than 40% on June 4, which wiped out close to $6 billion of the company’s market cap. This drop was after Bristol Myers Squibb (BMY) and Nektar reported preliminary results from the currently ongoing phase one and two study for NKTR-214 in combination with Opdivo for treating patients with stage four metastatic melanoma, renal cell carcinoma, and urothelial cancers. The price of Bristol-Myers Squibb stock also witnessed selling pressure and fell almost 3% on June 4.